{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:52:12Z","timestamp":1770295932127,"version":"3.49.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s12026-014-8615-z","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T07:01:43Z","timestamp":1419922903000},"page":"326-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future"],"prefix":"10.1007","volume":"61","author":[{"given":"Luca","family":"Cantarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Napodano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazaros I.","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"8615_CR1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340\u201354.","journal-title":"Autoimmun Rev"},{"key":"8615_CR2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncprheum0346","volume":"2","author":"LI Sakkas","year":"2006","unstructured":"Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:679\u201385.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"8615_CR3","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","volume":"48","author":"C Feghali-Bostwick","year":"2003","unstructured":"Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48:1956\u201363.","journal-title":"Arthritis Rheum"},{"key":"8615_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2010.09.010","volume":"10","author":"C Grossman","year":"2011","unstructured":"Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev. 2011;10:244\u20137.","journal-title":"Autoimmun Rev"},{"key":"8615_CR5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2008.07.022","volume":"8","author":"SB Randone","year":"2008","unstructured":"Randone SB, Guiducci S, Matucci-Cerinic M. Systemic sclerosis and infections. Autoimmun Rev. 2008;8:36\u201340.","journal-title":"Autoimmun Rev"},{"key":"8615_CR6","author":"A Lanteri","year":"2014","unstructured":"Lanteri A, Sobanski V, Langlois C, Lef\u00e8vre G, Hauspie C, Sanges S, Lambert M, Morell-Dubois S, Hatron PY, Hachulla E, Launay D, Dubucquoi S. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev. 2014. doi: 10.1016\/j.autrev.2014.07.003 .","journal-title":"Autoimmun Rev"},{"key":"8615_CR7","author":"S Trad","year":"2014","unstructured":"Trad S, Nosbaum A, Musset L, Ghillani-Dalbin P, Launay D, Costedoat-Chalumeau N, Saadoun D, Cabane J, Hachulla E, Hanslik T, Frances C. Systemic sclerosis and prevalence of monoclonal immunoglobulin. Autoimmun Rev. 2014. doi: 10.1016\/j.autrev.2014.08.016 .","journal-title":"Autoimmun Rev"},{"key":"8615_CR8","author":"M Versini","year":"2014","unstructured":"Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014. doi: 10.1016\/j.autrev.2014.07.001 .","journal-title":"Autoimmun Rev"},{"key":"8615_CR9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2014.03.003","volume":"13","author":"D Bernal-Bello","year":"2014","unstructured":"Bernal-Bello D. Garc\u00eda de Tena J, Sime\u00f3n-Aznar C, Fonollosa-Pla V. Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene? Autoimmun Rev. 2014;13:880\u20131.","journal-title":"Autoimmun Rev"},{"key":"8615_CR10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2013.12.002","volume":"13","author":"OJ Calixto","year":"2014","unstructured":"Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev. 2014;13:641\u201354.","journal-title":"Autoimmun Rev"},{"key":"8615_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.autrev.2013.10.002","volume":"13","author":"I Marie","year":"2014","unstructured":"Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, Bravard P, No\u00ebl D, Cailleux AF, Weber J, Lagoutte P, Benichou J, Levesque H. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev. 2014;13:151\u20136.","journal-title":"Autoimmun Rev"},{"key":"8615_CR12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.autrev.2013.05.002","volume":"12","author":"M Elhai","year":"2013","unstructured":"Elhai M, Avouac J, Kahan A, Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev. 2013;12:1052\u20137.","journal-title":"Autoimmun Rev"},{"key":"8615_CR13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.autrev.2013.02.003","volume":"12","author":"LT Osnes","year":"2013","unstructured":"Osnes LT, Nakken B, Bodolay E, Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies\u2014novel tool for diagnostics and patient follow-up. Autoimmun Rev. 2013;12:967\u201371.","journal-title":"Autoimmun Rev"},{"key":"8615_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.autrev.2012.07.007","volume":"12","author":"A Antico","year":"2012","unstructured":"Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012;12:127\u201336.","journal-title":"Autoimmun Rev"},{"key":"8615_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.autrev.2012.06.004","volume":"12","author":"L Iaccarino","year":"2013","unstructured":"Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12:363\u201373.","journal-title":"Autoimmun Rev"},{"key":"8615_CR16","doi-asserted-by":"crossref","first-page":"A502","DOI":"10.1016\/j.autrev.2011.12.003","volume":"11","author":"GC Hughes","year":"2012","unstructured":"Hughes GC. Progesterone and autoimmune disease. Autoimmun Rev. 2012;11:A502\u201314.","journal-title":"Autoimmun Rev"},{"key":"8615_CR17","doi-asserted-by":"crossref","first-page":"A422","DOI":"10.1016\/j.autrev.2011.11.020","volume":"11","author":"TP Lee","year":"2012","unstructured":"Lee TP, Chiang BL. Sex differences in spontaneous versus induced animal models of autoimmunity. Autoimmun Rev. 2012;11:A422\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.autrev.2011.06.008","volume":"11","author":"SC Farhat","year":"2011","unstructured":"Farhat SC, Silva CA, Orione MA, Campos LM, Sallum AM, Braga AL. Air pollution in autoimmune rheumatic diseases: a review. Autoimmun Rev. 2011;11:14\u201321.","journal-title":"Autoimmun Rev"},{"key":"8615_CR19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.autrev.2011.04.019","volume":"10","author":"V Liakouli","year":"2011","unstructured":"Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011;10:590\u20134.","journal-title":"Autoimmun Rev"},{"key":"8615_CR20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2011.04.016","volume":"10","author":"P Cipriani","year":"2011","unstructured":"Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R. Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmun Rev. 2011;10:641\u20136.","journal-title":"Autoimmun Rev"},{"key":"8615_CR21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","volume":"11","author":"KH Costenbader","year":"2012","unstructured":"Costenbader KH, Gay S, Alarc\u00f3n-Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2012;11:604\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.autrev.2013.04.004","volume":"12","author":"SA Jimenez","year":"2013","unstructured":"Jimenez SA, Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2013;12:1046\u201351.","journal-title":"Autoimmun Rev"},{"key":"8615_CR23","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","volume":"9","author":"B Ranque","year":"2010","unstructured":"Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9:A311\u20138.","journal-title":"Autoimmun Rev"},{"key":"8615_CR24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2007.12.004","volume":"7","author":"R Foti","year":"2008","unstructured":"Foti R, Leonardi R, Rondinone R, Di Gangi M, Leonetti C, Canova M, Doria A. Scleroderma-like disorders. Autoimmun Rev. 2008;7:331\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.autrev.2013.05.005","volume":"12","author":"MF Careta","year":"2013","unstructured":"Careta MF, Leite Cda C, Cresta F, Albino J, Tsunami M, Romiti R. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face. Autoimmun Rev. 2013;12:1064\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","volume":"13","author":"M Prete","year":"2014","unstructured":"Prete M, Fatone MC, Favoino E, Perosa F. Raynaud\u2019s phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014;13:655\u201367.","journal-title":"Autoimmun Rev"},{"key":"8615_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2010.09.008","volume":"10","author":"F Galluccio","year":"2011","unstructured":"Galluccio F, Matucci-Cerinic M. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev. 2011;10:241\u20133.","journal-title":"Autoimmun Rev"},{"key":"8615_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.autrev.2005.08.004","volume":"5","author":"L Chung","year":"2006","unstructured":"Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev. 2006;5:125\u20138.","journal-title":"Autoimmun Rev"},{"key":"8615_CR29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2011.04.025","volume":"10","author":"I Almeida","year":"2011","unstructured":"Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev. 2011;10:693\u2013701.","journal-title":"Autoimmun Rev"},{"key":"8615_CR30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton C, Farge-Bancel D, Kowal-Bielecka O, M\u00fcller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754\u201363.","journal-title":"Ann Rheum Dis"},{"key":"8615_CR31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","volume":"55","author":"SC Plastiras","year":"2006","unstructured":"Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55:598\u2013602.","journal-title":"Arthritis Rheum"},{"key":"8615_CR32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.autrev.2010.06.006","volume":"9","author":"S Lambova","year":"2010","unstructured":"Lambova S, M\u00fcller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmun Rev. 2010;9:761\u201370.","journal-title":"Autoimmun Rev"},{"key":"8615_CR33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.autrev.2006.12.006","volume":"6","author":"S Guiducci","year":"2007","unstructured":"Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev. 2007;6:520\u20133.","journal-title":"Autoimmun Rev"},{"key":"8615_CR34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","volume":"29","author":"VD Steen","year":"2003","unstructured":"Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29:315\u201333.","journal-title":"Rheum Dis Clin North Am"},{"key":"8615_CR35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","volume":"51","author":"L Guillevin","year":"2012","unstructured":"Guillevin L, B\u00e9rezn\u00e9 A, Seror R, Teixeira L, Pourrat J, Mahr A, Hachulla E, Agard C, Cabane J, Vanhille P, Harle JR, Deleveaux I, Mouthon L. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology. 2012;51:460\u20137.","journal-title":"Rheumatology"},{"key":"8615_CR36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.autrev.2013.03.013","volume":"12","author":"I Hollan","year":"2013","unstructured":"Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004\u201315.","journal-title":"Autoimmun Rev"},{"key":"8615_CR37","first-page":"157","volume":"31","author":"M Iudici","year":"2013","unstructured":"Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks\u2014a systematic review. Clin Exp Rheumatol. 2013;31:157\u201365.","journal-title":"Clin Exp Rheumatol"},{"key":"8615_CR38","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"AE Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841\u20137.","journal-title":"Arthritis Rheum"},{"key":"8615_CR39","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985\u201393.","journal-title":"Arthritis Rheum"},{"key":"8615_CR40","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, B\u00f6hm M. Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980\u20135.","journal-title":"Circulation"},{"key":"8615_CR41","first-page":"1407","volume":"19","author":"FM Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19:1407\u201314.","journal-title":"J Rheumatol"},{"key":"8615_CR42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3899\/jrheum.090668","volume":"37","author":"AL Herrick","year":"2010","unstructured":"Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, Denton CP. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol. 2010;37:116\u201324.","journal-title":"J Rheumatol"},{"key":"8615_CR43","first-page":"S17","volume":"30","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17\u201322.","journal-title":"Clin Exp Rheumatol"},{"key":"8615_CR44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, Pellerito R, Von M\u00fchlen CA, Vacca A, Airo P, Bartoli F, Fiori G, Bokarewa M, Riccieri V, Becker M, Avouac J, M\u00fcller-Ladner U, Distler O, Allanore Y, EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217\u201320.","journal-title":"Ann Rheum Dis"},{"key":"8615_CR45","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","volume":"63","author":"J Pope","year":"2011","unstructured":"Pope J, McBain D, Petrich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K. Imatinib in active diffuse cutaneous systemic sclerosis: results from a six-month, randomized, placebo-controlled, proof-of-concept study at a single center. Arthritis Rheum. 2011;63:3547\u201351.","journal-title":"Arthritis Rheum"},{"key":"8615_CR46","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar van","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, K\u00f6tter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Qu\u00e9r\u00e9 I, Rich \u00c9, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Soci\u00e9 G, Gratwohl A, Tyndall A, EBMT\/EULAR Scleroderma Study Group. Autologous stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. A randomized clinical trial. JAMA. 2014;311:2490\u20138.","journal-title":"JAMA"},{"key":"8615_CR47","first-page":"301","volume":"11","author":"G Rosa De","year":"2007","unstructured":"De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301\u20138.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"8615_CR48","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","volume":"11","author":"SV Kaveri","year":"2012","unstructured":"Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11:792\u20134.","journal-title":"Autoimmun Rev"},{"key":"8615_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","volume":"7","author":"JF Seite","year":"2008","unstructured":"Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev. 2008;7:435\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR50","first-page":"s33","volume":"11","author":"I Quinti","year":"2013","unstructured":"Quinti I, Pesce AM, Bonanni L, Rubino C, Pulvirenti F, Milito C. Clinical use of polyvalent immunoglobulins. Blood Transfus. 2013;11:s33\u20139.","journal-title":"Blood Transfus"},{"key":"8615_CR51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","volume":"342","author":"M Debr\u00e9","year":"1993","unstructured":"Debr\u00e9 M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342:945\u20139.","journal-title":"Lancet"},{"key":"8615_CR52","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","volume":"203","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med. 2006;203:789\u201397.","journal-title":"J Exp Med"},{"key":"8615_CR53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176\u201389.","journal-title":"Nat Rev Immunol"},{"key":"8615_CR54","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","volume":"190","author":"S Othy","year":"2013","unstructured":"Othy S, Hegde P, Topcu S, Sharma M, Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol. 2013;190:4535\u201341.","journal-title":"J Immunol"},{"key":"8615_CR55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484\u20136.","journal-title":"Science"},{"key":"8615_CR56","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","volume":"115","author":"N Li","year":"2005","unstructured":"Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115:3440\u201350.","journal-title":"J Clin Invest"},{"key":"8615_CR57","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","volume":"105","author":"RM Anthony","year":"2008","unstructured":"Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA. 2008;105:19571\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8615_CR58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670\u20133.","journal-title":"Science"},{"key":"8615_CR59","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/316452a0","volume":"316","author":"RB Parekh","year":"1985","unstructured":"Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316:452\u20137.","journal-title":"Nature"},{"key":"8615_CR60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/gut.31.4.431","volume":"31","author":"R Dube","year":"1990","unstructured":"Dube R, Rook GA, Steele J, Brealey R, Dwek R, Rademacher T, Lennard-Jones J. Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut. 1990;31:431\u20134.","journal-title":"Gut"},{"key":"8615_CR61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","volume":"111","author":"A Ephrem","year":"2008","unstructured":"Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715\u201322.","journal-title":"Blood"},{"key":"8615_CR62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2172-10-5","volume":"10","author":"M Barreto","year":"2009","unstructured":"Barreto M, Ferreira RC, Louren\u00e7o L, Moraes-Fontes MF, Santos E, Alves M, Carvalho C, Martins B, Andreia R, Viana JF, Vasconcelos C, Mota-Vieira L, Ferreira C, Demengeot J, Vicente AM. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGF-beta gene variants. BMC Immunol. 2009;10:5.","journal-title":"BMC Immunol"},{"key":"8615_CR63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0896-8411(91)90028-B","volume":"4","author":"A Sundblad","year":"1991","unstructured":"Sundblad A, Huetz F, Portno\u00ef D, Coutinho A. Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun. 1991;4:325\u201339.","journal-title":"J Autoimmun"},{"key":"8615_CR64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","volume":"135","author":"D Paquin Proulx","year":"2010","unstructured":"Paquin Proulx D, Aubin E, Lemieux R, Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol. 2010;135:422\u20139.","journal-title":"Clin Immunol"},{"key":"8615_CR65","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","volume":"101","author":"J Bayry","year":"2003","unstructured":"Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758\u201365.","journal-title":"Blood"},{"key":"8615_CR66","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.4049\/jimmunol.174.9.5837","volume":"174","author":"J Abe","year":"2005","unstructured":"Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol. 2005;174:5837\u201345.","journal-title":"J Immunol."},{"key":"8615_CR67","doi-asserted-by":"crossref","first-page":"e1002071","DOI":"10.1371\/journal.ppat.1002071","volume":"7","author":"C Ramakrishna","year":"2011","unstructured":"Ramakrishna C, Newo AN, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog. 2011;7:e1002071.","journal-title":"PLoS Pathog"},{"key":"8615_CR68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10238-005-0079-y","volume":"5","author":"A Ephrem","year":"2005","unstructured":"Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med. 2005;5:135\u201340.","journal-title":"Clin Exp Med"},{"key":"8615_CR69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"P Bruhns","year":"2003","unstructured":"Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003;18:573\u201381.","journal-title":"Immunity"},{"key":"8615_CR70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373\u20136.","journal-title":"Science"},{"key":"8615_CR71","doi-asserted-by":"crossref","unstructured":"Prabagar MG, Choi HJ, Park JY, Loh S, Kang YS. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. Clin Exp Med. 2013, epub ahead of print.","DOI":"10.1007\/s10238-013-0255-4"},{"key":"8615_CR72","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.intimp.2011.07.024","volume":"11","author":"A Baxley","year":"2011","unstructured":"Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2011;11:1663\u20137.","journal-title":"Int Immunopharmacol"},{"key":"8615_CR73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","volume":"17","author":"LR Pierce","year":"2003","unstructured":"Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241\u201351.","journal-title":"Transfus Med Rev"},{"key":"8615_CR74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","volume":"38","author":"J Dantal","year":"2013","unstructured":"Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275\u201384.","journal-title":"Am J Nephrol"},{"key":"8615_CR75","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb01462.x","volume":"123","author":"C Bodemer","year":"1990","unstructured":"Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123:545\u20136.","journal-title":"Br J Dermatol"},{"key":"8615_CR76","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1365-2230.1998.00378.x","volume":"23","author":"U Wollina","year":"1998","unstructured":"Wollina U, Looks A, Schneider R, Maak B. Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol. 1998;23:292\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"8615_CR77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","volume":"19","author":"Y Levy","year":"2000","unstructured":"Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, Shoenfeld Y. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin\u2014a preliminary report. Clin Rheumatol. 2000;19:207\u201311.","journal-title":"Clin Rheumatol"},{"key":"8615_CR78","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, Generini S, Matucci Cerinic M, Shoenfeld Y. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50:1005\u20137.","journal-title":"Arthritis Rheum"},{"key":"8615_CR79","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, Yamane K, Tamaki K. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology. 2005;44:824\u20136.","journal-title":"Rheumatology"},{"key":"8615_CR80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","volume":"66","author":"F Nacci","year":"2007","unstructured":"Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, Melchiorre D, Sapir T, Blank M, Shoenfeld Y, Pignone AM, Cerinic MM. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 2007;66:977\u20139.","journal-title":"Ann Rheum Dis"},{"key":"8615_CR81","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","volume":"156","author":"H Ihn","year":"2007","unstructured":"Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156:1058\u201360.","journal-title":"Br J Dermatol"},{"key":"8615_CR82","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","volume":"144","author":"S Schanz","year":"2008","unstructured":"Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008;144:585\u20137.","journal-title":"Arch Dermatol"},{"key":"8615_CR83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","volume":"28","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Aleksza M, Antal-Szalm\u00e1s P, Solt\u00e9sz P, Veres K, Sz\u00e1nt\u00f3 S, Szab\u00f3 Z, V\u00e9gv\u00e1ri A, Szamosi S, Lakos G, Sipka S, Szegedi G, Varga J, Sz\u00fccs G. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12\u00a0months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28:347\u201350.","journal-title":"Clin Rheumatol"},{"key":"8615_CR84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","volume":"42","author":"G Zandman-Goddard","year":"2012","unstructured":"Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:247\u201355.","journal-title":"Clin Rev Allergy Immunol"},{"key":"8615_CR85","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31:151\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"8615_CR86","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/03009742.2013.868510","volume":"43","author":"W Mauhin","year":"2014","unstructured":"Mauhin W, Rivi\u00e8re S, Cabane J, Tiev KP. Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis. Scand J Rheumatol. 2014;43:170\u20131.","journal-title":"Scand J Rheumatol"},{"key":"8615_CR87","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"M Blank","year":"2002","unstructured":"Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46:1689\u201390.","journal-title":"Arthritis Rheum"},{"key":"8615_CR88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2010.04295.x","volume":"163","author":"M Kajii","year":"2011","unstructured":"Kajii M, Suzuki C, Kashihara J, Kobayashi F, Kubo Y, Miyamoto H, Yuuki T, Yamamoto T, Nakae T. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin Exp Immunol. 2011;163:235\u201341.","journal-title":"Clin Exp Immunol"},{"key":"8615_CR89","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","volume":"69","author":"H Kudo","year":"2013","unstructured":"Kudo H, Jinnin M, Yamane K, Makino T, Kajihara I, Makino K, Honda N, Nakayama W, Fukushima S, Ihn H. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci. 2013;69:77\u201380.","journal-title":"J Dermatol Sci"},{"key":"8615_CR90","first-page":"275","volume":"33","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol. 2006;33:275\u201384.","journal-title":"J Rheumatol"},{"key":"8615_CR91","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2133.1998.02460.x","volume":"139","author":"A Grassegger","year":"1998","unstructured":"Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, Salmhofer W, Zahel B, Pinter G, Herold M, Klein G, Fritsch PO. Interferon-g in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol. 1998;139:639\u201348.","journal-title":"Br J Dermatol"},{"key":"8615_CR92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99\u2013104.","journal-title":"Clin Immunol"},{"key":"8615_CR93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1385\/CRIAI:29:3:321","volume":"29","author":"V Molina","year":"2005","unstructured":"Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29:321\u20136.","journal-title":"Clin Rev Allergy Immunol"},{"key":"8615_CR94","doi-asserted-by":"crossref","first-page":"829751","DOI":"10.1155\/2011\/829751","volume":"2011","author":"M Baleva","year":"2011","unstructured":"Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol. 2011;2011:829751.","journal-title":"Int J Rheumatol."},{"key":"8615_CR95","doi-asserted-by":"crossref","first-page":"A515","DOI":"10.1016\/j.autrev.2011.11.021","volume":"11","author":"M Lidar","year":"2012","unstructured":"Lidar M, Langevitz P. Pregnancy issues in scleroderma. Autoimmun Rev. 2012;11:A515\u20139.","journal-title":"Autoimmun Rev"},{"key":"8615_CR96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","volume":"8","author":"M \u00d8stensen","year":"2006","unstructured":"\u00d8stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I, Derksen R, Branch W, Motta M, Gordon C, Ruiz-Irastorza G, Spinillo A, Friedman D, Cimaz R, Czeizel A, Piette JC, Cervera R, Levy RA, Clementi M, De Carolis S, Petri M, Shoenfeld Y, Faden D, Valesini G, Tincani A. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.","journal-title":"Arthritis Res Ther"},{"key":"8615_CR97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/rheumatology\/ken174","volume":"47","author":"I Miniati","year":"2008","unstructured":"Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M. Pregnancy in systemic sclerosis. Rheumatology. 2008;47:16\u201328.","journal-title":"Rheumatology"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-014-8615-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8615-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T02:36:26Z","timestamp":1566182186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-014-8615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["8615"],"URL":"https:\/\/doi.org\/10.1007\/s12026-014-8615-z","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]}}}